Synthesis and anticonvulsant activity of 1,2-aminoalkanol derivatives

Acta Poloniae Pharmaceutica - Drug Research

Volumn 55, Issue 6, 1998, Pages 487-498

  Marona, Henryk ^a   Antkiewicz Michaluk, Lucyna ^b  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b Polska Akademia Nauk Oddzial w Krakowie   (Poland)

Author keywords

1,2 aminoalkanol derivatives; Anticonvulsant activity; Synthesis

Indexed keywords

2 AMINOBUTANOL; ALKANOL; CARBAMAZEPINE; PHENYTOIN; UNCLASSIFIED DRUG; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG SYNTHESIS; ELECTRIC SHOCK; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NEUROTOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; SEIZURE; SEIZURE THRESHOLD;

AMINO ALCOHOLS; ANIMALS; ANTICONVULSANTS; BINDING, COMPETITIVE; CONVULSANTS; INJECTIONS, INTRAPERITONEAL; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICE; PENTYLENETETRAZOLE; RATS; RATS, SPRAGUE-DAWLEY; SEIZURES; SYNAPTOSOMES;

EID: 0032407655     PISSN: 00016837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Lipicky R.J., Gilbert D.L., Stillman I.M.: Proc. Natl. Acad. Sci. USA 69, 1758 (1972).
2. Schauf C.L., Davis F.A., Marder J.: J. Pharmacol. Exp. Ther. 189, 538 (1974).
3. Catterall W.A.: Mol. Pharmacol. 20, 356 (1981).
4. Willow M., Kuenzel E.A., Catterall W.A.; Mol. Pharmacol. 25, 228 (1984).
5. Willow M., Catterall W.A.: Mol. Pharmacol. 22, 627 (1982).
6. Catteral W.A.: TIPS 8, 57 (1987).
7. Desmedt L.K., Niemegeers C.J., Janssen P.A.: Arzneim. Forsch. Drug Res. 25, 1408 (1975).
8. Ashton D., Wauguier A.: Psychopharmacology 65, 7 (1979).
9. Rogowski M.A., Porter R.J.: Pharmacol. Revs. 42, 224 (1990).
10. De Sarro G.B., Nistico G., Meldrum B.S.: Neuropharmacology 25, 695 (1986).
11. De Sarro G.B., Meldrum B.S., Nistico G.: Br J. Pharmacol. 93, 247 (1988).
12. Wong W.S., Rahwan R.G.: Gen. Pharmacol. 20, 309 (1989).
13. Marona H., Górka Z., Szneler E.: Pharmazie 53, 219 (1998).
14. Marona H.: Pharmazie 53, 405 (1998).
15. Krall R.L., Penry J.K., White B.G., Kupferberg H.J., Swinyard E.A.: Epilepsia 19, 409 (1978).
16. Czuczwar S.J., Kleinrok Z., Turski W.A.: CNS Drug Rev. 2, 452 (1996).
17. Hey P., Willey G.L.: Br. J. Pharmacol. 9, 471 (1954).
18. Gagnon P.E., Nadeau G., Cote R.: Can J. Chem. 30, 592 (1952).
19. Marona H., Gajewczyk L., Filipek B.: Acta Pol. Pharm. - Drug Res. 53, 47 (1996).
20. Porter R.J., Cereghino J.J., Gladding G.D., Hessie B.J., Kupferberg H.J., Scoville B., White B.G.: Cleveland. Clin. Q. 53, 293 (1984).
21. White H.S., Woodhead J.H., Franklin M.R., in: Levy R.H., Mattson R.H., Meldrum B.S. (Eds.): Experimental Selection, Quantification and Evaluation of Antieplipetic Drugs, pp. 99-110, New York, Raven Press (1995).
22. Kjeldgaard K.: Farm. Tidende 65, 461 (1955) C.A. 50, 10037e (1956).
23. Kjeldgaard K.: Farm. Tidende 65, 461 (1955) C.A. 50, 10037e (1956).
24. Gajewczyk L., Zejc A.: Pol. J. Chem. 64, 567 (1990).
25. Kalinina N.N., Kritsyn A.M., Likhosherstow A.M., Protopopowa T.B., Skoldinow A.P.: Med. Prom. SSSR 7,8(1963); C. A. 66, 9133c ( 1963).
26. Kalinina N.N., Kritsyn A.M., Likhosherstow A.M., Protopopowa T.B., Skoldinow A.P.: Med. Prom. SSSR 7,8(1963); C. A. 66, 9133c ( 1963).
27. Winstein S., Boschan R.: J. Am. Chem. Soc. 72, 4669 (1950).
28. Mulzac D., Scott K.R.: Epilepsia 34, 1141 (1993).